VM

Vishal Madaan

Associate Professor
Unit: School of Medicine
Department: Department of Psychiatry and NB Sciences
Office location and address
1670 Discovery Dr
Charlottesville, Virginia 22911
Education
Postgraduate Institute of Medical Sciences, Rohtak, India 1992, MD, MBBS
Residency, Creighton University Medical Center, Omaha, NE
Fellowship, Creighton University Medical Center, Omaha, NE
Long-term Antipsychotic Pediatric Safety Trial
Source: Duke University
June 21, 2019 – September 27, 2021
MD-PSYCH SPRITES: Sertraline Pediatric Registry for the Evaluation of Safety
Source: Duke University
July 17, 2012 – July 17, 2021
MD-PSYCH Open-Label Extension Study to Evaluate the Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Subjects with Attention Deficit/Hyperactivity Disorder (ADHD) in Conjuncti
Source: Supernus Pharmaceuticals, Inc.
November 09, 2016 – November 08, 2020
An Open-Label Extension Study of CM-AT for the Treatment of Children with Autism
Source: Curemark LLC
August 09, 2017 – August 08, 2020
MD_PSYCH Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of SPN-812 ER for the Treatment of Pediatric Patients with Attention Deficit/Hyperactivity Disorder (ADHD)
Source: SGS Life Sciences Services - Clinical Research
July 27, 2016 – July 26, 2020
MD-PSYCH An Open-label Long-term Safety Study of Vilazodone in Pediatric Patients with Major Depressive Disorder (VLZ-MD-23)
Source: FOREST LABORATORIES, INC.
September 28, 2015 – September 27, 2019
MD-PSYCH A Double Blind Randomized Placebo Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (Curemark 00103)
Source: Curemark LLC
September 27, 2016 – September 26, 2018
A Noninterventional Genotype/Phenotype Study of mGLuR Mutations inA Noninterventional Genotype/Phenotype Study of mGLuR Mutations inA Noninterventional Genotype/Phenotype Study of mGLuR Mutations in Childeren and Adolescents with ADHD
Source: Premier Research International, LLC
March 09, 2016 – October 15, 2017
MD-PSYCH An Open-Label Extension of the Safety and Tolerability of Memantine in Pediatric Patients
Source: Forest Research Institute, Inc.
December 05, 2012 – December 05, 2015
MD-PSYCH Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients
Source: Forest Research Institute, Inc.
December 05, 2012 – October 30, 2015
Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disorder or Schizophrenia
Source: Lilly USA, LLC
January 01, 2012 – January 31, 2015
MD PSYCH Flexible-Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episodes Associated with Bipolar 1 Disorder
Source: Schering Corporation
November 23, 2011 – November 23, 2014
Safety and Efficacy Study of SPD489-406
Source: Shire Development, LLC
July 26, 2012 – October 16, 2014
MD-PSYCH Study of the Safety and Toleability of Memantine in Pediatric Patients
Source: Forest Research Institute, Inc.
December 05, 2012 – October 16, 2014
Fixed-Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episodes Associated with Bipolar 1 Disorder
Source: Merck Sharp & Dohme Corp.
September 13, 2011 – September 13, 2014
Study of SPD 489
Source: Shire Development, LLC
July 26, 2012 – September 07, 2014
MD-PSYCH Rollover Study Evaluating Children and Adolescents with Tourette's Disorder
Source: Otsuka America Pharmaceutical, Inc.
July 12, 2011 – July 31, 2014
MD-PSYCH Initial Study Evaluating Children and Adolescents with Tourette's Disorder
Source: Otsuka America Pharmaceutical, Inc.
July 12, 2011 – June 30, 2014
MD-PSYCH Shire SPD554
Source: Shire Development, LLC
May 01, 2013 – May 01, 2014